Oral Presentation by Prof. Juerg Nussberger, MD, Today at 9.45am (EST): "CYT006-AngQb, a Vaccine Against Hypertension Targeting Angiotensin II,
Reduces Early-Morning and Day-Time Blood Pressure." The American Heart Association Publishes Today an Independent News Release
Excellent Long-Term Safety and Tolerability Profile Confirmed: no Vaccine-Related Adverse Events Reported in 12 Months Follow-Up Period.
ZURICH, Switzerland and ORLANDO, Florida, November 6 /PRNewswire/ -- Prof. Juerg Nussberger, MD, University Hospital of the Canton of Vaud (CHUV), in Lausanne, Switzerland, presents today detailed results of a placebo-controlled, double-blind phase IIa clinical trial with CYT006-AngQb in 72 patients with mild to moderate hypertension. In addition, the American Heart Association publishes today at the time of presentation an independent News Release about the vaccine CYT006-AngQb. For more information on this report please visit http://www.scientificsessions.org.
The study was designed to evaluate safety, tolerability, and exploratory efficacy of two dose levels of the vaccine (100 micrograms and 300 micrograms).For efficacy evaluation, the change in blood pressure from baseline to post-treatment was assessed in individual subjects by 24-hour ambulatory blood pressure monitoring.
Both dose levels of CYT006-AngQb tested were safe and well tolerated. The majority of side effects observed were transient and mostly mild local injection site reactions. During the entire safety follow-up period from month 4 to 12 after the first injection, no vaccine-related adverse events were reported. This confirms the excellent safety and tolerability profile of the vaccine and underscores its potential for long-term disease management.
All patients who received the vaccine mounted a strong antibody
response against ang
|SOURCE Cytos Biotechnology AG|
Copyright©2007 PR Newswire.
All rights reserved